Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 4/20 | 0.48 |
| ▸ | PTGIR | P43119 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31635254 | 0.79 | L3MBTL1 (0.61) | PTGIRHDAC1 | |
| SCHEMBL17085238 | 0.78 | EPHX2 (0.50) | EP300PTGIR | |
| SCHEMBL24754053 | 0.76 | SMPD1 (0.53) | — | |
| SCHEMBL19851582 | 0.76 | HDAC8 (0.76) | EP300PTGIRHDAC3HDAC4HDAC1 | |
| SCHEMBL15312634 | 0.74 | PTGIR (0.41) | EP300PTGIRHDAC3HDAC4HDAC1 | |
| SCHEMBL18373083 | 0.73 | HDAC8 (0.76) | EP300HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL18373086 | 0.73 | HDAC8 (0.76) | EP300HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL24642369 | 0.73 | HDAC3 (0.54) | EP300HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL24642739 | 0.72 | HDAC3 (0.54) | EP300HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL19591091 | 0.72 | SMPD1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150320891-A1 | Radioiodinated Fatty Acids | GE HEALTHCARE LIMITED (GG) | 2015-11-12 | — | — | US | disclosed |
| US-20150320891-A1 | Radioiodinated Fatty Acids | GE HEALTHCARE LIMITED (GG) | 2015-11-12 | — | — | US | disclosed |
| US-20150320891-A1 | Radioiodinated Fatty Acids | GE HEALTHCARE LIMITED (GG) | 2015-11-12 | — | — | US | disclosed |
| US-9138493-B2 | Radioiodinated fatty acids | GE HEALTHCARE LIMITED (GB) | 2015-09-22 | — | — | US | disclosed |
| US-9138493-B2 | Radioiodinated fatty acids | GE HEALTHCARE LIMITED (GB) | 2015-09-22 | — | — | US | disclosed |
| US-9138493-B2 | Radioiodinated fatty acids | GE HEALTHCARE LIMITED (GB) | 2015-09-22 | — | — | US | disclosed |
| EP-2651457-B1 | RADIOIODINATED FATTY ACIDS | GE HEALTHCARE UK LTD (GB) | 2014-10-29 | — | — | EP | disclosed |
| EP-2651457-A1 | RADIOIODINATED FATTY ACIDS | GE Healthcare UK Limited (GB) | 2013-10-23 | — | — | EP | disclosed |
| US-20130272960-A1 | RADIOIODINATED FATTY ACIDS | GE HEALTHCARE LIMITED (GB) | 2013-10-17 | — | — | US | disclosed |
| US-20130272960-A1 | RADIOIODINATED FATTY ACIDS | GE HEALTHCARE LIMITED (GB) | 2013-10-17 | — | — | US | disclosed |
| US-20130272960-A1 | RADIOIODINATED FATTY ACIDS | GE HEALTHCARE LIMITED (GB) | 2013-10-17 | — | — | US | disclosed |
| WO-2012080434-A1 | RADIOIODINATED FATTY ACIDS | GE HEALTHCARE LIMITED (GB) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080434-A1 | RADIOIODINATED FATTY ACIDS | GE HEALTHCARE LIMITED (GB) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320891-A1 | Radioiodinated Fatty Acids | FFAR3, FFAR1, FFAR2 | EP300 1458/4885PTGIR 450/4885HDAC3 615/4885 |
| US-20130272960-A1 | RADIOIODINATED FATTY ACIDS | FFAR3, FFAR1, FFAR2 | EP300 1458/4885PTGIR 450/4885HDAC3 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.